Lamictal

FDA approved Lamictal in the form of extended release tablets for the treatment of generalized tonic-clonic seizures

US Food and Drug Administration (FDA) approved the extension of lamotrigine indications in the form of extended-release tablets (Lamictal made by GlaxoSmithKline) as adjuvant treatment of generalized tonic-clonic seizures once daily in patients aged 13 years and older .

FDA decision is based on the results of a double-blind multi-center clinical trial lasting 19 weeks which involved 143 patients.